Skip to main content

SOP Investigator Responsibilities for Clinical Trial

 Title: Investigator Responsibilities

Introduction and Purpose:

The purpose of this Standard Operating Procedure (SOP) is to outline the requirements for conducting interventional clinical trials at the clinical site. This SOP can also serve as a guide for other types of clinical research studies, emphasizing the importance of quality and adherence to Good Clinical Practice (GCP) standards.


Scope:

The Principal Investigator (PI) of a clinical trial holds crucial responsibilities and obligations outlined in the Code of Federal Regulations (CFR) and Good Clinical Practice (GCP) guidelines. These responsibilities are essential to safeguard the rights, safety, and welfare of study participants and to ensure the credibility of study results.

The PI of a clinical trial is mandated to adhere to regulations governing human subject protection, including obtaining informed consent from participants and obtaining Institutional Review Board (IRB) review and approval, as specified in United States Food and Drug Administration (FDA) regulations (21 CFR §50 and 21 CFR §56).

Additionally, clinical trial investigators should follow the International Council on Harmonization (ICH) GCP guidelines, which guarantee the protection of trial subjects' rights, safety, and well-being. These guidelines align with principles rooted in the Declaration of Helsinki and ensure the credibility of clinical trial data.

The PI holds specific responsibilities, including compliance with the IRB-approved protocol, GCP guidelines, and relevant federal regulations. While the PI can delegate certain study tasks to sub-investigators, coordinators, and qualified study personnel, ultimate responsibility for overall study conduct remains with the investigator.

Definitions and Acronyms:

  • Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or publicly available data.
  • Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to assess its impact on health-related biomedical or behavioral outcomes.
  • CFR: Code of Federal Regulations
  • FDA: United States Food and Drug Administration
  • GCP: Good Clinical Practice
  • ICH: International Council on Harmonization
  • IRB: Institutional Review Board
  • PI: Principal Investigator
  • SOP: Standard Operating Procedure

Procedure:

Investigator Responsibilities:

In compliance with federal regulations and GCP, the PI assumes the responsibility of personally conducting or supervising the clinical trial. This includes:

  • Ensuring the clinical trial adheres to the signed investigational plan (protocol), investigator statement (Form FDA 1572 or Investigator Agreement for device studies), applicable regulations, and ICH GCP guidelines.
  • Safeguarding the rights, safety, and welfare of study subjects by obtaining informed consent and ensuring ongoing IRB review and approval.
  • Providing or ensuring adequate medical care for subjects during and after their participation in the trial.
  • Managing, maintaining, and accounting for investigational drugs, biologics, or devices.
  • Maintaining accurate study records and promptly reporting study data, including safety data, to the sponsor and/or regulatory agency.

Investigator Delegation of Tasks:

  • When the PI delegates study tasks or duties, they are responsible for offering comprehensive training and supervision to all delegates (see UUSOP#: 05 Delegation of Authority).

Investigator Supervision and Oversight:

The PI should establish a plan for supervising and overseeing the clinical trial, which includes:

  • Training study personnel and ensuring compliance with the study protocol, SOPs, and study-specific processes.

Ensuring that all staff involved in the study, including new personnel, receive adequate training. This includes:

  • Familiarity with the study's purpose and general protocol objectives.
  • A deep understanding of specific protocol details and attributes of the investigational product to perform assigned tasks.
  • Knowledge of GCPs and relevant regulatory requirements.
  • Competence to perform delegated tasks or appropriate training to do so.
  • Awareness of pertinent changes during the trial and additional training as needed.

Holding routine meetings with study personnel throughout the clinical trial to:

  • Review enrollment status, progress, and the condition of current study participants.
  • Assess the performance of delegated study tasks and duties, with reassignment as needed due to personnel turnover.
  • Ensure the appropriate conduct of the informed consent process, maintenance of IRB approval, and protocol compliance.
  • Verify the correct use, storage, and accountability of investigational products.
  • Confirm that clinical trial source data are complete and accurate, that data captured in case report forms or study databases align with source data, and that data queries and discrepancies identified by study monitors are handled and corrected correctly.
  • Review external safety reports and assess them against IRB reporting criteria.
  • Evaluate deviations or adverse trends and develop corrective and preventive actions when necessary.
  • Tracking trends in adverse events (AEs) and deviations may require the use of "master" logs rather than participant-specific logs. PIs should assess available resources for collecting aggregate AE and deviation data, such as Electronic Data Capture (EDC) systems and/or resources provided by study sponsors. If no other resource is available, the use of master logs is recommended.

Address medical and ethical issues that may arise during the trial.

  • It is crucial to document these investigator/study staff meetings, including the agenda, additional topics covered, and attendance. This documentation should be retained with the study records and made available for review upon request.
  • For investigator-initiated trials conducted at multiple clinical sites, the PI should facilitate effective communication with investigators and study staff at other participating sites, providing guidance, training, support, or corrective action as needed.


Investigator Training:

Clinical investigators should receive appropriate instruction and training before participating in clinical research. Training methods may include:

  • Mentorship with an experienced investigator.
  • Professional courses or seminars.
  • Completion of sponsor-required training programs.
  • Attendance at University of Utah clinical investigator training courses.

Investigators should maintain records of training and attendance at clinical research training events. Training topics should include:

  • The informed consent process.
  • FDA regulations for clinical research.
  • ICH guidelines for Good Clinical Practice.
  • IRB submissions, communications, and approval requirements.
  • CITI (Collaborative Institutional Training Initiative) program on human subjects research and GCP.
  • Detection, evaluation, and reporting of adverse events.
  • Accountability of investigational products.
  • The role of auditing and monitoring in clinical trials.

Materials Required:

  • Delegation of Authority log.
  • Protocol Training Log or other documentation of protocol-specific training.
  • GCP Essential Documents.

References:

  • 21 CFR Part 312 Subpart D: Responsibilities of Sponsors and Investigators.
  • ICH Guidance for Industry E6(R2): Good Clinical Practice.
  • FDA Guidance for Industry – Investigator Responsibilities (October 2009).

Document Approval:


Revision History:






Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more